Delivery Order SPE2DR25D1201-SPE2DR26FAJRT
Award Date 11/4/25
Potential Completion Date 11/5/25
Potential Value $16K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 tablets, with a ceiling value of $1,937.86. The award, issued on September 3, 2025, represents a firm fixed price delivery order with an ultimate completion date of September 4, 2025. This contract was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $16,523.11 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (16 count) on September 16, 2025, with completion expected by September 17, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment...
- The Defense Logistics Agency awarded a $9,639.92 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (unit dose, 10s) on September 16, 2025, with an ultimate completion date of September 17, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist used for acute...
- The Defense Logistics Agency awarded a delivery order valued at $1,398.53 to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit-dose packaging of 10 tablets. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive procurement process. The order is scheduled for completion by November 5, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. UBRELVY is an acute...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 29, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging. This competitively awarded, non-set-aside contract carries a ceiling value of $6,907.30 with firm fixed pricing and a completion date of October 30, 2025. The delivery order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. UBRELVY is an acute migraine treatment, supporting the Defense...
- The Defense Logistics Agency awarded a $19,560.62 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on September 18, 2025, with an ultimate completion date of September 19, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed price terms and directs performance to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is an acute migraine treatment, reflecting the company's role as a...
- The Defense Logistics Agency awarded a $13,431.90 delivery order to AmerisourceBergen Drug Corp for UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging of 10 tablets on April 24, 2025, with completion targeted for April 25, 2025. This competitively awarded, non-set-aside contract represents a firm fixed-price transaction under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $66,109.90 to AmerisourceBergen Drug Corp for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (16 count). This is a firm fixed price, competitively awarded contract with an ultimate completion date of September 22, 2025. The award was processed on September 19, 2025, with performance to occur at AmerisourceBergen's Conshohocken, Pennsylvania location. UBRELVY is a calcitonin gene-related peptide (CGRP)...
- The Defense Logistics Agency awarded a $16,964.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of UBRELVY (ubrogepant) 100 mg tablets in unit dose packaging (10-count). The contract, which is a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, has an ultimate completion date of September 11, 2025. UBRELVY is an FDA-approved acute migraine treatment...
- The Defense Logistics Agency awarded a delivery order valued at $4,164.75 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY (ubrogepant) is a calcitonin gene-related peptide receptor antagonist used...